Rethinking Diabetes Strategy: The Need for a Systems Approach

By João L. Carapinha

November 15, 2024

The World Health Organization’s (WHO) recent press release on the increasing global cases of diabetes highlights the urgent need for effective strategies to combat this rising health crisis. As the prevalence of diabetes continues to escalate, understanding the complexities associated with diabetes management has never been more critical.

Key Points from the WHO

1. Increasing Prevalence: The number of people living with diabetes has risen significantly, from 200 million in 1990 to 830 million in 2022. This trend is expected to continue, with projections suggesting over 780 million people will have diabetes by 2045.

2. Health and Economic Impact: Diabetes is a major contributor to mortality and morbidity, leading to significant health and economic burdens. It was the direct cause of 1.5 million deaths in 2019 and resulted in substantial healthcare expenditures, estimated at $966 billion in 2021.

3. Global Targets: The WHO has set five global diabetes coverage targets to be achieved by 2030, including ensuring 80% of people with diabetes are diagnosed, have good control of glycaemia and blood pressure, and receive necessary medications like statins. Also, 100% of people with type 1 diabetes should have access to affordable insulin and blood glucose self-monitoring.

Global Diabetes Strategies: Systems Approach and Feasibility Assessment

Awareness and Understanding

While policymakers may recognize the increasing prevalence and the need for urgent action, it remains vital to grasp the complex systemic changes required to meet the stated objectives. Diabetes is a multifaceted issue involving lifestyle factors, healthcare access, economic conditions, and societal structures.

Systems Approach

A systems approach would necessitate a comprehensive strategy that addresses the root causes of diabetes, including:

– Lifestyle Changes: Implementing widespread programs to promote healthy diets, physical activity, and smoking cessation. However, this requires significant investment in public health infrastructure and community engagement, which can be particularly challenging in low- and middle-income countries.
– Healthcare Access: Ensuring universal access to diabetes diagnosis, treatment, and ongoing care. This involves strengthening healthcare systems, which is especially daunting in regions with limited resources and infrastructure.
– Economic Factors: Addressing the economic burden of diabetes, which encompasses not only direct healthcare costs but also indirect costs such as lost productivity. This might involve innovative financing models and economic incentives to support diabetes prevention and care.

Feasibility and Implementation

The feasibility of achieving the WHO’s targets by 2030 raises questions. For example:

– Diagnosis and Control: Achieving 80% diagnosis and good control of glycaemia and blood pressure demands robust healthcare systems, widespread screening programs, and continuous monitoring—challenges that may persist across all countries, especially in low- and middle-income settings.
– Access to Medications: Ensuring 100% access to affordable insulin and blood glucose self-monitoring for people with type 1 diabetes is a considerable challenge, particularly in areas with limited healthcare resources and high medication costs.

Policy and Coordination

Effective policy-making needs to involve coordinated efforts across multiple sectors, including health, education, finance, and community development. However, the current approach may lack the necessary integration to drive meaningful change. For instance:

– Intersectoral Collaboration: There must be strong cooperation between various government departments, international organizations, and community groups to implement comprehensive diabetes prevention and control programs.
– Resource Allocation: Adequate resource allocation is crucial; however, this often encounters challenges due to competing health priorities and limited budgets in many countries.

In conclusion, while the WHO’s diabetes objectives are ambitious and necessary, achieving them requires a more holistic and integrated systems approach. Only by addressing the intricate factors contributing to the diabetes epidemic can we hope to meet these targets by 2030. Without such a comprehensive strategy, the likelihood of success remains uncertain.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.